McClarren Financial Advisors Inc. Buys New Shares in Thermo Fisher Scientific Inc. (NYSE:TMO)

McClarren Financial Advisors Inc. purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 302 shares of the medical research company’s stock, valued at approximately $157,000.

Several other large investors have also recently modified their holdings of the stock. Fiera Capital Corp grew its position in Thermo Fisher Scientific by 11.2% during the 4th quarter. Fiera Capital Corp now owns 155,552 shares of the medical research company’s stock worth $80,923,000 after acquiring an additional 15,629 shares during the last quarter. Three Bridge Wealth Advisors LLC bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $273,000. Naples Global Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 5.7% in the fourth quarter. Naples Global Advisors LLC now owns 756 shares of the medical research company’s stock worth $394,000 after buying an additional 41 shares during the period. Van ECK Associates Corp boosted its position in Thermo Fisher Scientific by 19.7% during the 4th quarter. Van ECK Associates Corp now owns 418,365 shares of the medical research company’s stock valued at $217,646,000 after buying an additional 68,927 shares during the period. Finally, Diversified Portfolios Inc. grew its holdings in Thermo Fisher Scientific by 6.3% in the 4th quarter. Diversified Portfolios Inc. now owns 641 shares of the medical research company’s stock worth $333,000 after acquiring an additional 38 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on TMO shares. Barclays dropped their target price on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. Scotiabank raised their price target on Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a “sector perform” rating in a research note on Monday, February 3rd. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective on the stock in a research report on Friday, January 10th. Finally, Wells Fargo & Company raised their target price on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. Four research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $658.00.

Insider Activity at Thermo Fisher Scientific

In related news, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the sale, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at $15,984,264.64. This trade represents a 26.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the transaction, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at approximately $9,582,009.17. This trade represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 20,125 shares of company stock valued at $11,231,699 over the last 90 days. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Down 1.3 %

Shares of NYSE:TMO opened at $538.31 on Thursday. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88. The stock has a market capitalization of $205.90 billion, a price-to-earnings ratio of 32.57, a PEG ratio of 3.18 and a beta of 0.77. The stock has a fifty day simple moving average of $548.02 and a two-hundred day simple moving average of $571.52. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has authorized a share buyback plan on Friday, November 15th that authorizes the company to buyback $4.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 2% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.